TY - JOUR
T1 - Exploring common mechanisms of adverse drug reactions and disease phenotypes through network-based analysis
AU - Firoozbakht, Farzaneh
AU - Elkjaer, Maria Louise
AU - Handy, Diane E.
AU - Wang, Rui Sheng
AU - Chervontseva, Zoe
AU - Rarey, Matthias
AU - Loscalzo, Joseph
AU - Baumbach, Jan
AU - Tsoy, Olga
PY - 2025/2
Y1 - 2025/2
N2 - The need for a deeper understanding of adverse drug reaction (ADR) mechanisms is vital for improving drug safety and repurposing. This study introduces Drug Adverse Reaction Mechanism Explainer (DREAMER), a network-based framework that uses a comprehensive knowledge graph to uncover molecular mechanisms underlying ADRs and disease phenotypes. By examining shared phenotypes of drugs and diseases and their effects on protein-protein interaction networks, DREAMER identifies proteins linked to ADR mechanisms. Applied to 649 ADRs, DREAMER identified molecular mechanisms for 67 ADRs, including ventricular arrhythmia and metabolic acidosis, and emphasized pathways like GABAergic signaling and coagulation proteins in personality disorders and intracranial hemorrhage. We further demonstrate the application of DREAMER in drug repurposing and propose sotalol, ranolazine, and diltiazem as candidate drugs to be repurposed for cardiac arrest. In summary, DREAMER effectively detects molecular mechanisms underlying phenotypes, emphasizing the importance of network-based analyses with integrative data for enhancing drug safety and accelerating the discovery of novel therapeutic strategies.
AB - The need for a deeper understanding of adverse drug reaction (ADR) mechanisms is vital for improving drug safety and repurposing. This study introduces Drug Adverse Reaction Mechanism Explainer (DREAMER), a network-based framework that uses a comprehensive knowledge graph to uncover molecular mechanisms underlying ADRs and disease phenotypes. By examining shared phenotypes of drugs and diseases and their effects on protein-protein interaction networks, DREAMER identifies proteins linked to ADR mechanisms. Applied to 649 ADRs, DREAMER identified molecular mechanisms for 67 ADRs, including ventricular arrhythmia and metabolic acidosis, and emphasized pathways like GABAergic signaling and coagulation proteins in personality disorders and intracranial hemorrhage. We further demonstrate the application of DREAMER in drug repurposing and propose sotalol, ranolazine, and diltiazem as candidate drugs to be repurposed for cardiac arrest. In summary, DREAMER effectively detects molecular mechanisms underlying phenotypes, emphasizing the importance of network-based analyses with integrative data for enhancing drug safety and accelerating the discovery of novel therapeutic strategies.
KW - adverse drug reaction
KW - clinical phenotypes
KW - CP: systems biology
KW - disease phenotype
KW - drug repurposing
KW - drug safety
KW - network diffusion
KW - network-based analysis
U2 - 10.1016/j.crmeth.2025.100990
DO - 10.1016/j.crmeth.2025.100990
M3 - Journal article
C2 - 39954672
AN - SCOPUS:85217886280
SN - 2667-2375
VL - 5
JO - Cell Reports Methods
JF - Cell Reports Methods
IS - 2
M1 - 100990
ER -